The company has around 25 projects in the pipeline and five Nanobodies in clinical development, which combine the benefits of conventional antibody drugs with some of the features of small-molecule drugs. Nanobodies have potential uses in treating inflammation, haematology, immuno-oncology and oncology. Sanofi acquired Ablynx in 2018 to continue developing Nanobody-based therapeutic programs for multiple disease targets with single multi-specific molecules.